-
MRE11 Lactylation Drives TNBC Radioresistance
2026-08-20
The reference study identifies lactate-dependent MRE11 Lys673 lactylation as a DNA-repair mechanism that protects triple-negative breast cancer cells from radiotherapy. It further shows that Saikosaponin D activates an HIF1α/HDAC5 pathway to reduce this modification, linking metabolic reprogramming to a potentially actionable radiosensitization strategy.
-
O-GlcNAcylation Rewires Wnt-Driven Bone Formation
2026-08-20
The reference study identifies O-GlcNAcylation as a required metabolic intermediary linking Wnt signaling to osteoblast differentiation, aerobic glycolysis, and bone formation. Its central mechanistic finding is that Wnt3a modifies PDK1 at Ser174, stabilizing PDK1 and redirecting glucose metabolism toward lactate production, with implications for fracture healing and anabolic osteoporosis research.
-
Gemcitabine Workflows for DNA Damage Assays
2026-08-19
Build reproducible Gemcitabine experiments around dose–time matrices, checkpoint readouts, and orthogonal apoptosis measurements rather than a single viability endpoint. This guide also shows how insights from IL-6/GP130 cancer biology can inform carefully controlled combination hypotheses without overstating the evidence.
-
Disodium Bicinchoninate in Translational Assays
2026-08-19
Oxidative-stress models can reveal endothelial mechanisms only when pathway biology and assay chemistry are interpreted together. This thought-leadership article connects the EZH2–inflammation–autophagy findings reported in H2O2-challenged endothelial cells with a practical strategy for using Disodium bicinchoninate as an aqueous-compatible biochemical reagent, while defining its translational boundaries.
-
Fenipentol: Practical Assay Workflows
2026-08-18
Fenipentol, also called 1-Phenyl-1-pentanol, gives researchers a versatile starting point for secretion, receptor, and inflammation-linked assays. This guide converts its physicochemical profile and historical choleretic use into controlled workflows while separating product-specific evidence from findings on a related positional isomer.
-
Entecavir Resistance Risk: A 2024 Meta-analysis
2026-08-18
This systematic review and meta-analysis provides the first pooled estimates of hepatitis B virus resistance to entecavir and tenofovir over time, separating treatment-naive from nucleos(t)ide-experienced populations. The findings show low long-term resistance risk with entecavir in treatment-naive participants, substantially higher risk after prior nucleos(t)ide exposure, and no detected pooled tenofovir resistance within the available evidence base.
-
Epinephrine Bitartrate in Adrenergic Assay Design
2026-08-17
Epinephrine Bitartrate is more than a broad receptor stimulant: it is a useful probe for separating adrenergic signaling, physiological phenotype, and assay timing. This guide uses the vernakalant atrial fibrillation trial to develop a translational framework for interpreting (-)-Epinephrine (+)-bitartrate experiments without confusing receptor activation with rhythm conversion.
-
Caspase-3/NDUFS1 Axis in Trichothecene ROS
2026-08-16
The reference preprint identifies caspase-3-mediated cleavage of mitochondrial NDUFS1 and ER-localized ERO1α as coordinated drivers of trichothecene-induced oxidative stress. Its findings provide a mechanistic framework for studying mitochondrial dysfunction and for designing assays that distinguish membrane-potential loss from broader ROS and apoptotic signaling.
-
Sodium Nitroprusside in Sex-Specific Vascular Assays
2026-08-15
Build more informative vascular experiments with Sodium Nitroprusside as a controllable nitric oxide donor for smooth muscle and platelet assays. This workflow connects ex vivo vasodilation measurements with the sex-stratified hypertension findings of a conscious-mouse study, helping researchers separate vascular responsiveness from neural and hormonal regulation.
-
Cirsium setidens and Doxorubicin Cardiotoxicity
2026-08-14
A July 2024 Phytomedicine study shows that hydroethanolic Cirsium setidens extract protects cardiomyocytes from doxorubicin-induced mitochondrial injury through an AMPK–PGC-1α–NRF1–SOD axis while preserving doxorubicin-associated cancer-cell apoptosis. Its multimodel design, spanning rat cardiomyocytes, mice, and human induced pluripotent stem cell-derived cardiomyocytes, provides a useful preclinical framework for cardioprotection research.
-
Sulfaphenazole: Reliable CYP2C9 Assays
2026-08-14
Learn how Sulfaphenazole, SKU C4131, can support interpretable CYP2C9 inhibition, cell-function, and vascular assay workflows. This scenario-based guide separates enzyme potency from cytotoxicity, addresses solvent and storage variables, and provides practical selection criteria grounded in product data and published evidence.
-
Epinephrine in Local Anesthesia: Systemic Effects
2026-08-13
This review examines how epinephrine improves local anesthesia while producing dose- and route-dependent systemic sympathomimetic effects. Its central practical conclusion is that a 1:200,000 concentration can usually provide effective anesthetic duration and depth while avoiding unnecessarily high epinephrine exposure.
-
Sulfo-Cy5 NHS Ester for Aqueous Immune Imaging
2026-08-13
Sulfo-Cy5 NHS ester enables near-infrared protein labeling in aqueous workflows, making it useful for solvent-sensitive probes, immune-cell imaging, and VLA-4 assays. This practical guide connects its conjugation chemistry with the dendritic-cell and tumor-microenvironment findings of a recent nanostructure study while separating established evidence from workflow recommendations.
-
Allosteric PDK4 Inhibitors for Metabolic Disease
2026-08-12
This 2019 Journal of Medicinal Chemistry study identified anthraquinone-derived allosteric inhibitors of pyruvate dehydrogenase kinase 4 (PDK4), with compound 8c combining nanomolar biochemical activity, favorable drug-like profiling, and efficacy in metabolic and allergic disease models. The work provides a mechanistically distinct scaffold for preclinical PDK4 inhibitor development while also illustrating the need to separate docking-based hypotheses from experimentally established target engagement.
-
Harpagoside Targets EGFR-TKI Resistance in Lung Cancer
2026-08-12
The reference study shows that harpagoside can enhance gefitinib and paclitaxel responses in EGFR-mutant lung adenocarcinoma models by suppressing Nrf2-associated resistance, EMT, apoptosis evasion, and ferroptosis protection. Its combination of resistance modeling, transcriptomics, functional assays, and xenograft or metastasis experiments provides a useful framework for investigating multi-process treatment resistance.